drugset / Trial / NCT00107900

Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement

NCT00107900

Phase 2 Completed 606 enrolled Daiichi Sankyo
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients having total hip replacement surgery.

Timeline

Start
2005-01
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 15 mg Oral
Subject Edoxaban Small molecule 30 mg Oral
Subject Edoxaban Small molecule 60 mg Oral
Subject Edoxaban Small molecule 120 mg Oral